Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Harm Westdorp(Radboud University Nijmegen), Winald R. Gerritsen(Amsterdam UMC Location Vrije Universiteit Amsterdam)

Journal for ImmunoTherapy of Cancer

November 14, 2019

10.1186/s40425-019-0787-6

Cited by 113

Related Papers

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

|New England Journal of Medicine|2017|3.4k

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

|Annals of Oncology|2019|484

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

|The Lancet Oncology|2012|357